Expansion6 Jan 2026, 05:42 pm
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at J.P. Morgan Healthcare Conference
AI Summary
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., will introduce three new oncology biosimilars at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications. The company is also planning to integrate as a wholly owned subsidiary of Biocon Limited, strengthening its global leadership in biosimilar insulins and GLP-1 peptide generics to cover the full spectrum of diabetes care. This integration is expected to be completed no later than March 31, 2026.
Key Highlights
- Introduction of three new oncology biosimilars - Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®)
- These new assets represent an over $75 billion opportunity, or approximately 35% of the global oncology pharmaceutical market
- Biocon Biologics is planning to integrate as a wholly owned subsidiary of Biocon Limited
- The integration is expected to be completed no later than March 31, 2026
- The integration will strengthen Biocon’s global position to lead in diabetes, oncology, and immunology - therapeutic areas that together account for nearly 40% of global pharmaceutical revenues